XML 379 R52.htm IDEA: XBRL DOCUMENT
v3.26.1

Other disclosures (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Remuneration |
Schedule of direct and indirect voting rights in subsidiaries and other investments | ​
​ | ​ | ​
​ | ​ ​ ​ | 2025
​ | ​ | Company’s
​ | ​ | voting
​ | ​ | rights
​ | ​ | %
Subsidiaries | ​ | ​
Aptuit Global LLC, Princeton, USA |  | 100
Aptuit (Verona) SRL, Verona, Italy |  | 100
Aptuit (Oxford) Ltd., Abingdon, UK |  | 100
Cyprotex Discovery Ltd., Manchester, UK |  | 100
Cyprotex Ltd., Manchester, UK |  | 100
Cyprotex US, LLC., Framingham, USA |  | 100
Evotec (France) SAS, Toulouse, France |  | 100
Evotec ID (Lyon) SAS, Marcy l’Étoile, France |  | 100
Evotec (Hamburg) GmbH, Hamburg, Germany |  | 100
Evotec GT GmbH, Orth an der Donau, Austria* |  | 100
Evotec (India) Private Limited, Thane, India* |  | 100
Evotec International GmbH, Hamburg, Germany |  | 100
Evotec (UK) Ltd., Abingdon, UK |  | 100
Evotec (US), Inc., Princeton, USA |  | 100
Just - Evotec Biologics, Inc., Seattle, USA |  | 100
Evotec (Modena) Srl, Medolla, Italy | ​ | 100
NephThera GmbH, Hamburg, Germany | ​ | 100
Evotec Asia Pte. Ltd., Shenton, Singapore | ​ | 100
​
​ | ​ | ​
​ | ​ ​ ​ | 2025
​ | ​ | Company’s
​ | ​ | voting
​ | ​ | rights
​ | ​ | %
Associates |  | ​
Breakpoint Therapeutics GmbH, Hamburg, Germany | ​ | 34.03
Centauri Therapeutics Ltd., Cheshire, UK |  | 22.18
EIR Biotherapies S.r.l., Mirandola (MO), Italy |  | 24.66
Eternygen GmbH, Berlin, Germany* |  | 24.97
Quantro Therapeutics GmbH, Vienna, Austria |  | 38.79
TAG Therapeutics GmbH, Vienna, Austria |  | 20.16
Topas Therapeutics GmbH, Hamburg, Germany |  | 23.86
​ | ​ | ​
Other Investments |  | ​
Aeovian Pharmaceuticals Inc., San Francisco, USA |  | 2.32
ArgoBio SAS, Paris, France | ​ | 8.17
Aurobac Therapeutics SAS, Lyon, France |  | 12.50
Autobahn Labs, LLC, Palo Alto, CA USA |  | 10.53
Blacksmith Medicines Inc., San Diego, CA USA |  | 17.97
Cajal Neuroscience Inc., Seattle, USA |  | 1.18
Carma Fund I, Munich, Germany |  | 10.00
Celmatix Inc., New York, USA |  | 7.47
Curie Bio LLC, Boston, USA |  | 0.10
Curie Bio Seed Fund I LP, Boston, USA |  | 2.83
Extend S.r.l., Rome, Italy | ​ | 9.10
Fibrocor LLP, Toronto, Canada | ​ | 16.26
Fibrocor Therapeutics, Inc., Toronto, Canada | ​ | 7.65
IMIDomics Inc., San Rafael, CA, USA | ​ | 6.64
Immunitas Therapeutics Inc.*, Waltham, USA | ​ | 5.54
Leon Nanodrugs GmbH, Munich, Germany | ​ | 3.99
Mission BioCapital V LP, Cambridge, USA | ​ | 3.64
Pluristyx Inc., Seattle, USA |  | 3.79
Sernova Corp., Ontario, Canada | ​ | 4.73
Thelior Bio, Oxford, UK | ​ | 1.18
Tubulis GmbH, Munich, Germany | ​ | 3.33
Verto Therapeutics Inc., Boston, USA | ​ | 4.16
* | in liquidation
Management Board |
Remuneration |
Schedule of remuneration granted to the members of the Management Board and remuneration accrued for the members of the Supervisory Board | ​
​ | ​ | ​ | ​ | ​
in k€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024
Short-term employee benefits |  | 5,503 | ​ | 4,238
Termination benefits | ​ | 1,506 | ​ | 1,360
Stock-based compensation |  | 247 | ​ | (2,231)
Total Remuneration |  | 7,256 | ​ | 3,367
Supervisory Board |
Remuneration |
Schedule of remuneration granted to the members of the Management Board and remuneration accrued for the members of the Supervisory Board | ​
​ | ​ | ​ | ​ | ​
in k€ | ​ ​ ​ | 2025 | ​ ​ ​ | 2024
Total remuneration of the supervisory board |  | 670 | ​ | 641

X
- Definition Disclosure of remuneration + References No definition available. + Details
Name: | evo_DisclosureOfRemunerationTableTextBlock
Namespace Prefix: | evo_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Remuneration + References No definition available. + Details
Name: | evo_RemunerationLineItems
Namespace Prefix: | evo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for interests in other entities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 1 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_1&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=evo_SupervisoryBoardMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |